{
    "nctId": "NCT00171314",
    "briefTitle": "The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer",
    "officialTitle": "The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 527,
    "primaryOutcomeMeasure": "Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage I-IIIa breast cancer\n* Postmenopausal\n* Recent surgery for breast cancer\n\nExclusion Criteria:\n\n* Metastatic disease\n* Invasive bilateral disease\n* Clinical or radiological evidence of existing fracture in spine or hip\n\nOther protocol-defined inclusion / exclusion criteria may apply.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}